Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Administration of low-dose epoetin-alpha facilitates adherence to ribavirin in triple therapy with pegylated interferon-alpha-2b and telaprevir.
Ishida H, Sakane S, Toyama T, Fukutomi K, Kimura K, Sugimoto A, Hibino K, Tamura T, Iwasaki T, Iwasaki R, Hasegawa H, Sakakibara Y, Yamada T, Nakazuru S, Mita E. Ishida H, et al. Among authors: mita e. Hepatol Res. 2014 Oct;44(10):E84-91. doi: 10.1111/hepr.12224. Epub 2014 Jan 7. Hepatol Res. 2014. PMID: 23957840
The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan.
Hiramatsu N, Kasahara A, Nakanishi F, Toyama T, Tsujii M, Tsuji S, Kanto T, Takehara T, Kato M, Yoshihara H, Naito M, Katayama K, Hijioka T, Hagiwara H, Kubota S, Oshita M, Meren H, Masuzawa M, Haruna Y, Mita E, Suzuki K, Hayashi N. Hiramatsu N, et al. Among authors: mita e. Hepatol Res. 2004 Jul;29(3):142-147. doi: 10.1016/j.hepres.2004.03.008. Hepatol Res. 2004. PMID: 15203077
Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?
Hiramatsu N, Oze T, Tsuda N, Kurashige N, Koga K, Toyama T, Yasumaru M, Kanto T, Takehara T, Kasahara A, Kato M, Yoshihara H, Katayama K, Hijioka T, Hagiwara H, Kubota S, Oshita M, Haruna Y, Mita E, Suzuki K, Ishibashi K, Hayashi N. Hiramatsu N, et al. Among authors: mita e. Hepatol Res. 2006 Jul;35(3):185-9. doi: 10.1016/j.hepres.2006.03.008. Epub 2006 May 4. Hepatol Res. 2006. PMID: 16678478
Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis.
Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, Inoue Y, Igura T, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Yoshihara H, Inoue A, Imai Y, Kato M, Kiso S, Kanto T, Takehara T, Kasahara A, Hayashi N. Kurokawa M, et al. Among authors: mita e. Hepatol Res. 2009 May;39(5):432-8. doi: 10.1111/j.1872-034X.2008.00477.x. Epub 2009 Jan 16. Hepatol Res. 2009. PMID: 19207583
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Oze T, et al. Among authors: mita e. J Viral Hepat. 2009 Aug;16(8):578-85. doi: 10.1111/j.1365-2893.2009.01116.x. Epub 2009 Jun 22. J Viral Hepat. 2009. PMID: 19552663
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin.
Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizuki K, Imanaka K, Kaneko A, Oshita M, Hagiwara H, Mita E, Nagase T, Ito T, Inui Y, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Hiramatsu N, et al. Among authors: mita e. J Viral Hepat. 2009 Aug;16(8):586-94. doi: 10.1111/j.1365-2893.2009.01106.x. Epub 2009 Jun 22. J Viral Hepat. 2009. PMID: 19552664
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hagiwara H, Oshita M, Mita E, Fukui H, Inada M, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Miyagi T, Hohsui A, Ishida H, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Inoue Y, et al. Among authors: mita e. J Viral Hepat. 2010 May;17(5):336-44. doi: 10.1111/j.1365-2893.2009.01182.x. Epub 2009 Aug 12. J Viral Hepat. 2010. PMID: 19678893
192 results